Global Acute Lung Injury Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts; 2023 to 2031

Report
120 Pages
February 2023
Region: Global
Acute Market Reports
ID: 5742665

The market for Acute Lung Injury is expected to rise at a CAGR of 3.5% during the forecast period of 2023 to 2031. Acute Lung Injury (ALI) is a severe medical condition in which lung tissues become inflamed and damaged, causing difficulty breathing and low blood oxygen levels. Infections, chemical exposure, and trauma are significant risk factors for ALI. The condition can progress to acute respiratory distress syndrome (ARDS), which has a high mortality rate of around 40% with the current standard of care. Increased alcohol and tobacco consumption among the population is causing an increase in lung injury cases, which is expected to drive the market for acute lung injury treatments. Additionally, air pollution and obesity can cause acute and chronic lung injuries. An increase in the elderly population is likely to create lucrative growth opportunities for industry vendors. Vendors are concentrating on the development, production, and distribution of novel therapies in order to increase their market share in the global acute lung injury treatment market.

R&D of Novel Therapies Enhancing Acute Lung Injury Treatment Market Growth

An increase in infectious diseases, such as influenza and pneumonia, can lead to a rise in ALI cases. Diverse studies investigate the use of biological agents, such as surfactant replacement therapy and anti-inflammatory drugs, to treat ALI. Despite advancements in surgical techniques and perioperative management, the incidence of postoperative ALI continues to be quite high. Postoperative ALI occurs in approximately 0% to 2% of patients undergoing major surgery. Depending on the type of surgery, the incidence of postoperative ALI ranges from 2-4% after thoracotomy for lung resection to 0.5% after cardiac surgery. In spite of advances in diagnosis and treatment, morbidity and mortality remain high. The development of advanced technologies, such as mechanical ventilation, oxygen therapy, and extracorporeal membrane oxygenation (ECMO), has increased the survival rate of patients with acute lung injury (ALI). Emerging treatment for ALI, ECMO involves oxygenating the patient's blood outside the body and then returning it to the patient. Thus, research and development of new technologies and an increased emphasis on improving patient outcomes are expected to contribute to the growth of the acute lung injury treatment market in the near future.

Increase in Unhealthy Habits in the Population

Tobacco use is a significant risk factor for ALI and COPD. The nicotine found in cigarettes can cause inflammation and scarring of the lungs. This can make it more difficult for the lungs to function normally, thereby increasing the risk of ALI and COPD. Thus, it is anticipated that the increase in the number of smokers will boost the market growth in the coming years. Electronic cigarettes and vaping products are gaining popularity among the general public. These products have been associated with an increase in ALI cases. According to the Centres for Disease Control and Prevention (CDC), the majority of E-cigarette or Vaping Use-associated Lung Injury (EVALI) cases are linked to tetrahydrocannabinol (THC)-containing e-cigarette or vaping products obtained from informal sources such as friends, family, or in-person or online dealers. In addition, the CDC received reports of 2,807 hospitalized cases of EVLAI in February 2020.

E-cigarette aerosols contain a variety of chemicals, including nicotine, flavorings, and solvents, which can be inhaled deeply into the lungs. These chemicals can cause irritation and inflammation, which can result in ALI symptoms including shortness of breath, chest pain, and coughing. In addition, it has been discovered that some e-cigarettes contain harmful substances, such as heavy metals and diacetyl, which can increase the risk of ALI. In the near future, the market statistics for acute lung injury treatment are likely to be influenced by the rising popularity of e-cigarettes and vaping products.

A rise in the elderly population causes a decline in lung function, making the elderly more vulnerable to ALI. There is a decline in lung elasticity, an increase in inflammation, and a weakening of the immune system in the elderly. These factors increase the susceptibility of the elderly to infections and inflammation.

COPD and heart disease are prevalent among the elderly. In this age group, the use of multiple medications also increases the risk of ALI. Therefore, the increase in the elderly population is anticipated to enhance market dynamics in the coming years.

Increase in Hospital Preference

During the forecast period, the hospital end-user segment is anticipated to dominate the acute lung injury treatment market. ALI is a serious medical condition that necessitates immediate and specialized hospital care. The proper treatment and management of ALI require a month of hospitalization for the majority of patients. For the treatment of ALI, hospitals have access to specialized equipment and technologies, such as mechanical ventilators, ECMO machines, and High-frequency Oscillating Ventilators (HFOV). In addition to pulmonologists, critical care specialists, and respiratory therapists, hospitals employ a team of trained healthcare professionals.

Cost of Treatment to Challenge the Market Growth

The primary obstacles impeding the growth of the acute lung injury market are the high cost of treatment drugs and the absence of a specific treatment for disease diagnosis. The low rate of digital radiography adoption is one of the significant factors inhibiting market expansion.

Direct Injury to Dominate the Market

The Acute Lung Injury Market is segmented by injury type into Direct Injury and Indirect Injury. The Direct Injury segment has a larger market share than the Indirect Injury segment. During the forecast period, the direct Injury segment will be the dominant market segment. Approximately 55% of Lung Injuries are caused by Direct Injury, and according to our research, this proportion will increase over the coming years.

Respiratory Tract Diseases Devices Expected to be the Fastest Growing Market

The Acute Lung Injury Market is segmented by Therapy into Therapy by Medication and Devices. The Medication consists of pharmacotherapy, fluid management, and inhaled nitric oxide. The devices are further classified as Mechanical ventilation and Adjunctive procedures. A CAGR of 5% is anticipated for Respiratory Tract Diseases devices throughout the forecast period. As a number of therapies are used as a supportive treatment for Acute Lung Injury, the medication segment dominates the devices segment. As numerous improvements are being made to medications for the treatment of lung injury, the medication segment will continue to dominate the market over the forecast period. In the segment of therapy, pharmacotherapy has a larger market share. Approximately 39% of ALI patients are treated with nitric oxide.

North America to Lead the Revenues, While Asia Emerges as Growth Leader

The most recent market forecast for acute lung injury treatment projects that North America will hold the largest share during the forecast period. In the near future, an increase in vaping adoption and the high prevalence of ALI are anticipated to boost market revenue in the region. Approximately 1 in 20 people in the United States, including several middle and high school students, use electronic cigarettes or vapes, according to the CDC. In 2021, North America dominated the market with a 35% revenue share. The North American region is anticipated to experience a CAGR of 3.5% throughout the forecast period. The increasing prevalence of the ALI is a significant factor in market dominance. The market is driven by the ongoing advances and research in the medical field for specific treatment of ALI, with the majority of key players located in North America. A high incidence of Acute Lung Injury is also observed in North America and Europe. In the U.S. approximately. In Europe and the United States, approximately 7.5% and 6.9% of all deaths are caused by respiratory diseases, respectively. The Asia-Pacific region is an emerging market for ALI due to the larger population and higher percentage of the geriatric population in China and Japan, respectively 16% and 28%. In recent years, the incidence of respiratory diseases in India has increased from 4.5% to 6.4%. In addition, increased awareness of health diagnostics is a significant factor in the expansion of market share. The market in this region is driven by the increasing prevalence of lung infections and the rising demand for medical devices and medications for the treatment of patients. The Asia-Pacific region holds approximately 25% of the market and is projected to grow at a CAGR of 5% during the forecast period.

Strong Drug Pipeline to Enhance Market Shares

The market is fragmented due to the presence of a significant number of market players and hospitals. Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, Great Ormond Street Hospital, Apollo Hospitals, Tokyo Medical University Hospital, The Prince Charles Hospital, Helios Hospital, and Aster Hospitals are among the industry's key players.

Various molecules from various companies are currently in Phase II, Phase I, and Preclinical development. Similarly, the preclinical and discovery portfolios of universities contain seven and three molecules, respectively. Altor BioScience Corporation, Apeptico, Forschung und Entwicklung GmbH, Commence Bio, Inc., CompleGen, Inc., FirstString Research, Inc., GlaxoSmithKline Plc, Histocell S.L., Navigen Pharmaceuticals, Inc., Noxxon Pharma AG, Quark, Pharmaceuticals, Inc., S-Evans Biosciences, Inc., Silence Therapeutics Plc, Stemedica Cell Technologies, Inc., Windtree Therapeutics, Inc are some of the key market players.

Key Developments in the market include:

Peroxitech Inc., a biopharmaceutical company developing a novel peptide for the treatment of ALI, announced the conclusion of a US$ 25 Mn Series A fundraising transaction in December 2022. The funding would be used to develop and market PIP-2, the leading candidate.
In April 2020, Chimerix, a biopharmaceutical company whose mission is to expedite the development of drugs for serious diseases, initiated a Phase 2/3 study on the use of dociparstat sodium (DSTAT) in COVID-19 patients with ALI.

Historical Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Acute Lung Injury Treatment market are as follows:

Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report
Micro and macro environment factors that are currently influencing the Acute Lung Injury Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Injury Type

Direct Injury
Indirect Injury

Therapy

Medication
Pharmacotherapy
Fluid Management
Nitric Oxide Inhalation
Devices
Mechanical Ventilation
Adjunctive Procedure Devices

End-user

Hospitals
Specialty Centres
Others

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Acute Lung Injury Treatment market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2031.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Acute Lung Injury Treatment market?
Which is the largest regional market for Acute Lung Injury Treatment market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East Africa?
Which are the key trends driving Acute Lung Injury Treatment market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Acute Lung Injury Treatment market worldwide?

This product will be delivered within 2 business days.

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Acute Lung Injury Treatment Market
2.2. Global Acute Lung Injury Treatment Market, By Injury Type, 2022 (US$ Million)
2.3. Global Acute Lung Injury Treatment Market, By Therapy, 2022 (US$ Million)
2.4. Global Acute Lung Injury Treatment Market, By End-user, 2022 (US$ Million)
2.5. Global Acute Lung Injury Treatment Market, By Geography, 2022 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2022

3. Acute Lung Injury Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Acute Lung Injury Treatment Market Vendors
3.2. Strategies Adopted by Acute Lung Injury Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2022 Versus 2031

4. Acute Lung Injury Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Acute Lung Injury Treatment Market Value, 2021 - 2031, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2022 Versus 2031
5.3. Market Segmentation
5.3.1. Direct Injury
5.3.2. Indirect Injury

6. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2022 Versus 2031
6.3. Market Segmentation
6.3.1. Medication
6.3.1.1. Pharmacotherapy
6.3.1.2. Fluid Management
6.3.1.3. Nitric Oxide Inhalation
6.3.2. Devices
6.3.2.1. Mechanical Ventilation
6.3.2.2. Adjunctive Procedure Devices

7. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2022 Versus 2031
7.3. Market Segmentation
7.3.1. Hospitals
7.3.2. Specialty Centres
7.3.3. Others

8. North America Acute Lung Injury Treatment Market, 2021-2031, USD (Million)
8.1. Market Overview
8.2. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
8.3. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
8.4. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
8.5.Acute Lung Injury Treatment Market: By Region, 2021-2031, USD (Million)
8.5.1.North America
8.5.1.1. U.S.
8.5.1.1.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
8.5.1.1.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
8.5.1.1.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
8.5.1.2. Canada
8.5.1.2.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
8.5.1.2.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
8.5.1.2.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
8.5.1.3. Rest of North America
8.5.1.3.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
8.5.1.3.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
8.5.1.3.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)

9. UK and European Union Acute Lung Injury Treatment Market, 2021-2031, USD (Million)
9.1. Market Overview
9.2. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
9.3. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
9.4. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
9.5.Acute Lung Injury Treatment Market: By Region, 2021-2031, USD (Million)
9.5.1.UK and European Union
9.5.1.1. UK
9.5.1.1.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
9.5.1.1.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
9.5.1.1.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
9.5.1.2. Germany
9.5.1.2.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
9.5.1.2.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
9.5.1.2.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
9.5.1.3. Spain
9.5.1.3.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
9.5.1.3.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
9.5.1.3.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
9.5.1.4. Italy
9.5.1.4.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
9.5.1.4.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
9.5.1.4.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
9.5.1.5. France
9.5.1.5.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
9.5.1.5.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
9.5.1.5.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
9.5.1.6. Rest of Europe
9.5.1.6.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
9.5.1.6.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
9.5.1.6.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)

10. Asia Pacific Acute Lung Injury Treatment Market, 2021-2031, USD (Million)
10.1. Market Overview
10.2. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
10.3. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
10.4. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
10.5.Acute Lung Injury Treatment Market: By Region, 2021-2031, USD (Million)
10.5.1.Asia Pacific
10.5.1.1. China
10.5.1.1.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
10.5.1.1.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
10.5.1.1.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
10.5.1.2. Japan
10.5.1.2.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
10.5.1.2.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
10.5.1.2.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
10.5.1.3. India
10.5.1.3.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
10.5.1.3.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
10.5.1.3.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
10.5.1.4. Australia
10.5.1.4.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
10.5.1.4.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
10.5.1.4.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
10.5.1.5. South Korea
10.5.1.5.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
10.5.1.5.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
10.5.1.5.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
10.5.1.6. Rest of Asia Pacific
10.5.1.6.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
10.5.1.6.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
10.5.1.6.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)

11. Latin America Acute Lung Injury Treatment Market, 2021-2031, USD (Million)
11.1. Market Overview
11.2. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
11.3. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
11.4. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
11.5.Acute Lung Injury Treatment Market: By Region, 2021-2031, USD (Million)
11.5.1.Latin America
11.5.1.1. Brazil
11.5.1.1.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
11.5.1.1.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
11.5.1.1.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
11.5.1.2. Mexico
11.5.1.2.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
11.5.1.2.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
11.5.1.2.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
11.5.1.3. Rest of Latin America
11.5.1.3.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
11.5.1.3.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
11.5.1.3.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)

12. Middle East and Africa Acute Lung Injury Treatment Market, 2021-2031, USD (Million)
12.1. Market Overview
12.2. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
12.3. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
12.4. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
12.5.Acute Lung Injury Treatment Market: By Region, 2021-2031, USD (Million)
12.5.1.Middle East and Africa
12.5.1.1. GCC
12.5.1.1.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
12.5.1.1.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
12.5.1.1.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
12.5.1.2. Africa
12.5.1.2.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
12.5.1.2.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
12.5.1.2.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)
12.5.1.3. Rest of Middle East and Africa
12.5.1.3.1. Acute Lung Injury Treatment Market: By Injury Type, 2021-2031, USD (Million)
12.5.1.3.1. Acute Lung Injury Treatment Market: By Therapy, 2021-2031, USD (Million)
12.5.1.3.1. Acute Lung Injury Treatment Market: By End-user, 2021-2031, USD (Million)

13. Company Profile
13.1. Mayo Clinic
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Portfolio
13.1.4. Strategic Initiatives
13.2. Johns Hopkins Hospital
13.2.1. Company Overview
13.2.2. Financial Performance
13.2.3. Product Portfolio
13.2.4. Strategic Initiatives
13.3. Cleveland Clinic
13.3.1. Company Overview
13.3.2. Financial Performance
13.3.3. Product Portfolio
13.3.4. Strategic Initiatives
13.4. Great Ormond Street Hospital
13.4.1. Company Overview
13.4.2. Financial Performance
13.4.3. Product Portfolio
13.4.4. Strategic Initiatives
13.5. Apollo Hospitals
13.5.1. Company Overview
13.5.2. Financial Performance
13.5.3. Product Portfolio
13.5.4. Strategic Initiatives
13.6. Tokyo Medical University Hospital
13.6.1. Company Overview
13.6.2. Financial Performance
13.6.3. Product Portfolio
13.6.4. Strategic Initiatives
13.7. The Prince Charles Hospital
13.7.1. Company Overview
13.7.2. Financial Performance
13.7.3. Product Portfolio
13.7.4. Strategic Initiatives
13.8. Helios Hospital
13.8.1. Company Overview
13.8.2. Financial Performance
13.8.3. Product Portfolio
13.8.4. Strategic Initiatives
13.9. Aster Hospitals
13.9.1. Company Overview
13.9.2. Financial Performance
13.9.3. Product Portfolio
13.9.4. Strategic Initiatives
13.10. Others
13.10.1. Company Overview
13.10.2. Financial Performance
13.10.3. Product Portfolio
13.10.4. Strategic Initiatives

List of Figures
Figure 1 Global Acute Lung Injury Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Acute Lung Injury Treatment Market: Quality Assurance
Figure 5 Global Acute Lung Injury Treatment Market, By Injury Type, 2022
Figure 6 Global Acute Lung Injury Treatment Market, By Therapy, 2022
Figure 7 Global Acute Lung Injury Treatment Market, By End-user, 2022
Figure 8 Global Acute Lung Injury Treatment Market, By Geography, 2022
Figure 9 Market Geographical Opportunity Matrix - Global Acute Lung Injury Treatment Market, 2022
Figure 10 Market Positioning of Key Acute Lung Injury Treatment Market Players, 2022
Figure 11 Global Acute Lung Injury Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
Figure 12 Global Acute Lung Injury Treatment Market, By Injury Type, 2022 Vs 2031, %
Figure 13 Global Acute Lung Injury Treatment Market, By Therapy, 2022 Vs 2031, %
Figure 14 Global Acute Lung Injury Treatment Market, By End-user, 2022 Vs 2031, %
Figure 15 U.S. Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 16 Canada Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 17 Rest of North America Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 18 UK Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 19 Germany Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 20 Spain Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 21 Italy Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 22 France Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 23 Rest of Europe Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 24 China Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 25 Japan Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 26 India Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 27 Australia Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 28 South Korea Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 29 Rest of Asia Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 30 Brazil Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 31 Mexico Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 32 Rest of Latin America Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 33 GCC Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 34 Africa Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031
Figure 35 Rest of Middle East and Africa Acute Lung Injury Treatment Market (US$ Million), 2021 - 2031

List of Tables
Table 1 Global Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 2 Global Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 3 Global Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 4 Global Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 5 Global Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 6 North America Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 7 North America Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 8 North America Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 9 North America Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 10 North America Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 11 U.S. Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 12 U.S. Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 13 U.S. Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 14 U.S. Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 15 U.S. Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 16 Canada Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 17 Canada Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 18 Canada Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 19 Canada Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 20 Canada Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 21 Rest of North America Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 22 Rest of North America Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 23 Rest of North America Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 24 Rest of North America Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 25 Rest of North America Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 26 UK and European Union Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 27 UK and European Union Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 28 UK and European Union Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 29 UK and European Union Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 30 UK and European Union Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 31 UK Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 32 UK Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 33 UK Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 34 UK Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 35 UK Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 36 Germany Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 37 Germany Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 38 Germany Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 39 Germany Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 40 Germany Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 41 Spain Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 42 Spain Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 43 Spain Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 44 Spain Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 45 Spain Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 46 Italy Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 47 Italy Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 48 Italy Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 49 Italy Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 50 Italy Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 51 France Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 52 France Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 53 France Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 54 France Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 55 France Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 56 Rest of Europe Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 57 Rest of Europe Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 58 Rest of Europe Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 59 Rest of Europe Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 60 Rest of Europe Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 61 Asia Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 62 Asia Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 63 Asia Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 64 Asia Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 65 Asia Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 66 China Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 67 China Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 68 China Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 69 China Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 70 China Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 71 Japan Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 72 Japan Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 73 Japan Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 74 Japan Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 75 Japan Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 76 India Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 77 India Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 78 India Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 79 India Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 80 India Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 81 Australia Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 82 Australia Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 83 Australia Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 84 Australia Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 85 Australia Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 86 South Korea Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 87 South Korea Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 88 South Korea Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 89 South Korea Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 90 South Korea Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 91 Latin America Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 92 Latin America Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 93 Latin America Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 94 Latin America Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 95 Latin America Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 96 Brazil Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 97 Brazil Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 98 Brazil Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 99 Brazil Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 100 Brazil Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 101 Mexico Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 102 Mexico Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 103 Mexico Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 104 Mexico Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 105 Mexico Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 106 Rest of Latin America Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 107 Rest of Latin America Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 108 Rest of Latin America Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 109 Rest of Latin America Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 110 Rest of Latin America Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 111 Middle East and Africa Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 112 Middle East and Africa Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 113 Middle East and Africa Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 114 Middle East and Africa Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 115 Middle East and Africa Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 116 GCC Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 117 GCC Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 118 GCC Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 119 GCC Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 120 GCC Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 121 Africa Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 122 Africa Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 123 Africa Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 124 Africa Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 125 Africa Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)
Table 126 Rest of Middle East and Africa Acute Lung Injury Treatment Market By Injury Type, 2021-2031, USD (Million)
Table 127 Rest of Middle East and Africa Acute Lung Injury Treatment Market By Therapy, 2021-2031, USD (Million)
Table 128 Rest of Middle East and Africa Acute Lung Injury Treatment Market By Medication, 2021-2031, USD (Million)
Table 129 Rest of Middle East and Africa Acute Lung Injury Treatment Market By Devices, 2021-2031, USD (Million)
Table 130 Rest of Middle East and Africa Acute Lung Injury Treatment Market By End-user, 2021-2031, USD (Million)

Companies Mentioned

Mayo Clinic
Johns Hopkins Hospital
Cleveland Clinic
Great Ormond Street Hospital
Apollo Hospitals
Tokyo Medical University Hospital
The Prince Charles Hospital
Helios Hospital
Aster Hospitals
Altor BioScience Corporation
Apeptico
Forschung und Entwicklung GmbH
Commence Bio Inc.
CompleGen Inc.
FirstString Research Inc.
GlaxoSmithKline Plc
Histocell S.L.
Navigen Pharmaceuticals Inc.
Noxxon Pharma AG
Quark
Pharmaceuticals Inc.
S-Evans Biosciences Inc.
Silence Therapeutics Plc
Stemedica Cell Technologies Inc.
Windtree Therapeutics Inc

PURCHASE OPTIONS

Hard Copy

Single User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
Hard Copy	A printed copy of the product will be shipped to you.		€4350EUR$4,500USD£3,739GBP
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€6284EUR$6,500USD£5,401GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8700EUR$9,000USD£7,478GBP